Federal Circuit Ruling in Amarin v. Hikma Increases Liability for Generic Drug Makers
In a noteworthy decision last month, the Federal Circuit in Amarin v. Hikma has set a precedent likely to increase the liability faced by generic drug manufacturers. According to legal experts Jeremiah Helm and Sean Murray at Knobbe Martens, the ruling suggests that there will be a rise in allegations of induced infringement following the…